The Clorox Company (NYSE:CLX) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,141 shares of the company's stock after acquiring an additional 3,364 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Clorox were worth $7,981,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Integral Investment Advisors Inc. increased its position in Clorox by 4.1% during the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock worth $279,000 after purchasing an additional 67 shares in the last quarter. Sound View Wealth Advisors Group LLC increased its position in Clorox by 6.1% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock worth $218,000 after purchasing an additional 77 shares in the last quarter. Wedbush Securities Inc. increased its position in Clorox by 1.2% during the 4th quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock worth $1,238,000 after purchasing an additional 94 shares in the last quarter. Global X Japan Co. Ltd. increased its position in Clorox by 3.0% during the 4th quarter. Global X Japan Co. Ltd. now owns 3,272 shares of the company's stock worth $531,000 after purchasing an additional 95 shares in the last quarter. Finally, Aviance Capital Partners LLC increased its position in Clorox by 3.2% during the 4th quarter. Aviance Capital Partners LLC now owns 3,180 shares of the company's stock worth $516,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. DA Davidson decreased their price target on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. Evercore ISI set a $140.00 price target on Clorox and gave the stock an "underperform" rating in a report on Tuesday, May 6th. UBS Group decreased their price target on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Wells Fargo & Company decreased their price target on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, Barclays decreased their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a report on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $151.23.

Clorox Stock Performance

Shares of CLX stock traded down $2.41 on Thursday, hitting $127.24. 1,889,670 shares of the stock traded hands, compared to its average volume of 1,348,361. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The company has a market capitalization of $15.68 billion, a PE ratio of 34.77, a PEG ratio of 2.62 and a beta of 0.60. The Clorox Company has a 1-year low of $126.99 and a 1-year high of $171.37. The company's fifty day moving average is $137.00 and its 200 day moving average is $150.20.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business's revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.71 earnings per share. On average, equities research analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.57% of the stock is owned by corporate insiders.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.